Specialised pro-resolving mediators of inflammation in inflammatory arthritis

Anne Barden; M. Moghaddami; Emilie Mas; Michael Phillips; L.G. Cleland; Trevor Mori

doi:10.1016/j.plefa.2016.03.004

Specialised pro-resolving mediators of inflammation in inflammatory arthritis

Anne Barden, M. Moghaddami, Emilie Mas, Michael Phillips, L.G. Cleland, Trevor Mori

Research output: Contribution to journal › Article

52 Citations (Scopus)

Abstract

© 2016 Elsevier Ltd. Introduction: Specialised pro-resolving mediators (SPM) are derived from n-3 long chain polyunsaturated fatty acids (n-3FA). They promote resolution of inflammation and may contribute to the beneficial effects of n-3FA in patients with arthritis. This study compared SPM in knee effusions and plasma of patients with arthritis taking n-3FA, and plasma of healthy volunteers taking n-3FA. Methods: Thirty six patients taking n-3FA undergoing arthrocentesis for an inflammatory knee effusion and 36 healthy volunteers who had taken n-3FA (2.4 g/day) for 4 weeks were studied. SPM in synovial fluid and plasma were measured by liquid chromatography-tandem mass spectrometry included 18-hydroxyeicosapentaenoic acid (18-HEPE), the precursor of the E-series SPM (RvE1, RvE2, RvE3, 18R-RvE3), and 17-hydroxydocosahexaenoic acid (17-HDHA), the precursor of the D-series SPM (RvD1, 17R-RvD1, RvD2). Other SPM included protectin D1 (PD1), 10S,17S-dihydroxydocosahexaenoic acid (10,17S-DHDHA), maresin-1 (MaR-1) and 14-hydroxydocosahexaenoic acid (14-HDHA) derived from docosahexaenoic acid (DHA). Results: E- and D-series SPM and the precursors 18-HEPE and 17-HDHA were present in synovial fluid and plasma of the patients with inflammatory arthritis. Plasma SPM were negatively related to erythrocyte sedimentation rate in arthritis patients (P

Original language	English
Pages (from-to)	24-29
Journal	Prostaglandins Leukotrienes and Essential Fatty Acids
Volume	107
DOIs	https://doi.org/10.1016/j.plefa.2016.03.004
Publication status	Published - 2016

Access to Document

10.1016/j.plefa.2016.03.004

Fingerprint Dive into the research topics of 'Specialised pro-resolving mediators of inflammation in inflammatory arthritis'. Together they form a unique fingerprint.

Cite this

Barden, A., Moghaddami, M., Mas, E., Phillips, M., Cleland, L. G., & Mori, T. (2016). Specialised pro-resolving mediators of inflammation in inflammatory arthritis. Prostaglandins Leukotrienes and Essential Fatty Acids, 107, 24-29. https://doi.org/10.1016/j.plefa.2016.03.004

@article{9e0922140803413cac413119be1d67ba,

title = "Specialised pro-resolving mediators of inflammation in inflammatory arthritis",

abstract = "{\textcopyright} 2016 Elsevier Ltd. Introduction: Specialised pro-resolving mediators (SPM) are derived from n-3 long chain polyunsaturated fatty acids (n-3FA). They promote resolution of inflammation and may contribute to the beneficial effects of n-3FA in patients with arthritis. This study compared SPM in knee effusions and plasma of patients with arthritis taking n-3FA, and plasma of healthy volunteers taking n-3FA. Methods: Thirty six patients taking n-3FA undergoing arthrocentesis for an inflammatory knee effusion and 36 healthy volunteers who had taken n-3FA (2.4 g/day) for 4 weeks were studied. SPM in synovial fluid and plasma were measured by liquid chromatography-tandem mass spectrometry included 18-hydroxyeicosapentaenoic acid (18-HEPE), the precursor of the E-series SPM (RvE1, RvE2, RvE3, 18R-RvE3), and 17-hydroxydocosahexaenoic acid (17-HDHA), the precursor of the D-series SPM (RvD1, 17R-RvD1, RvD2). Other SPM included protectin D1 (PD1), 10S,17S-dihydroxydocosahexaenoic acid (10,17S-DHDHA), maresin-1 (MaR-1) and 14-hydroxydocosahexaenoic acid (14-HDHA) derived from docosahexaenoic acid (DHA). Results: E- and D-series SPM and the precursors 18-HEPE and 17-HDHA were present in synovial fluid and plasma of the patients with inflammatory arthritis. Plasma SPM were negatively related to erythrocyte sedimentation rate in arthritis patients (P",

author = "Anne Barden and M. Moghaddami and Emilie Mas and Michael Phillips and L.G. Cleland and Trevor Mori",

year = "2016",

doi = "10.1016/j.plefa.2016.03.004",

language = "English",

volume = "107",

pages = "24--29",

journal = "Prostaglandins, Leukotrienes & Essential Fatty Acids",

issn = "0952-3278",

publisher = "Elsevier",

}

TY - JOUR

T1 - Specialised pro-resolving mediators of inflammation in inflammatory arthritis

AU - Barden, Anne

AU - Moghaddami, M.

AU - Mas, Emilie

AU - Phillips, Michael

AU - Cleland, L.G.

AU - Mori, Trevor

PY - 2016

Y1 - 2016

N2 - © 2016 Elsevier Ltd. Introduction: Specialised pro-resolving mediators (SPM) are derived from n-3 long chain polyunsaturated fatty acids (n-3FA). They promote resolution of inflammation and may contribute to the beneficial effects of n-3FA in patients with arthritis. This study compared SPM in knee effusions and plasma of patients with arthritis taking n-3FA, and plasma of healthy volunteers taking n-3FA. Methods: Thirty six patients taking n-3FA undergoing arthrocentesis for an inflammatory knee effusion and 36 healthy volunteers who had taken n-3FA (2.4 g/day) for 4 weeks were studied. SPM in synovial fluid and plasma were measured by liquid chromatography-tandem mass spectrometry included 18-hydroxyeicosapentaenoic acid (18-HEPE), the precursor of the E-series SPM (RvE1, RvE2, RvE3, 18R-RvE3), and 17-hydroxydocosahexaenoic acid (17-HDHA), the precursor of the D-series SPM (RvD1, 17R-RvD1, RvD2). Other SPM included protectin D1 (PD1), 10S,17S-dihydroxydocosahexaenoic acid (10,17S-DHDHA), maresin-1 (MaR-1) and 14-hydroxydocosahexaenoic acid (14-HDHA) derived from docosahexaenoic acid (DHA). Results: E- and D-series SPM and the precursors 18-HEPE and 17-HDHA were present in synovial fluid and plasma of the patients with inflammatory arthritis. Plasma SPM were negatively related to erythrocyte sedimentation rate in arthritis patients (P

AB - © 2016 Elsevier Ltd. Introduction: Specialised pro-resolving mediators (SPM) are derived from n-3 long chain polyunsaturated fatty acids (n-3FA). They promote resolution of inflammation and may contribute to the beneficial effects of n-3FA in patients with arthritis. This study compared SPM in knee effusions and plasma of patients with arthritis taking n-3FA, and plasma of healthy volunteers taking n-3FA. Methods: Thirty six patients taking n-3FA undergoing arthrocentesis for an inflammatory knee effusion and 36 healthy volunteers who had taken n-3FA (2.4 g/day) for 4 weeks were studied. SPM in synovial fluid and plasma were measured by liquid chromatography-tandem mass spectrometry included 18-hydroxyeicosapentaenoic acid (18-HEPE), the precursor of the E-series SPM (RvE1, RvE2, RvE3, 18R-RvE3), and 17-hydroxydocosahexaenoic acid (17-HDHA), the precursor of the D-series SPM (RvD1, 17R-RvD1, RvD2). Other SPM included protectin D1 (PD1), 10S,17S-dihydroxydocosahexaenoic acid (10,17S-DHDHA), maresin-1 (MaR-1) and 14-hydroxydocosahexaenoic acid (14-HDHA) derived from docosahexaenoic acid (DHA). Results: E- and D-series SPM and the precursors 18-HEPE and 17-HDHA were present in synovial fluid and plasma of the patients with inflammatory arthritis. Plasma SPM were negatively related to erythrocyte sedimentation rate in arthritis patients (P

U2 - 10.1016/j.plefa.2016.03.004

DO - 10.1016/j.plefa.2016.03.004

M3 - Article

C2 - 27033423

VL - 107

SP - 24

EP - 29

JO - Prostaglandins, Leukotrienes & Essential Fatty Acids

JF - Prostaglandins, Leukotrienes & Essential Fatty Acids

SN - 0952-3278

ER -